MAPK8, mitogen-activated protein kinase 8, 5599

N. diseases: 520; N. variants: 4
Disease: melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE In conclusion, our broad-in-depth work suggests that SHARPIN promotes melanoma development via p38 and JNK/c-Jun pathways through upregulation of Rap1 expression. 31401046 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Collectively, our data show that JNK2 activity is specifically required for melanoma cell proliferation, invasiveness, and BRAFi resistance and that this activity is most important in the context of JNK1 suppression, thus providing a compelling rationale for the development of JNK2 selective inhibitors as a potential therapy for the treatment of melanoma. 31063355 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Although the FDA has approved some JNK inhibitors for melanoma, the agency has not approved JNK inhibitors for ovarian cancer. 31639019 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE VE-cadherin-mediated integrin signaling occurred through specific activation of SRC, ERK and JNK, including AKT in melanoma. 27966446 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE MALT1 promotes melanoma progression through JNK/c-Jun signaling. 28759024 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Induction of MDA-9/syntenin in melanoma was found to occur in a thrombin-independent signaling pathway and involves the PAR-1/c-Src/Rho GTPases Rac1 and Cdc42/c-Jun N-terminal kinase axis resulting in the activation of paxillin, NF-κB, and matrix metalloproteinase-2 (MMP-2). 25505176 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.100 GeneticVariation disease BEFREE Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. 25814555 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.100 GeneticVariation disease BEFREE Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. 23624923 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE By showing that down-regulation of CCL2-driven signals by SAHA and temozolomide via JNK contributes to reduce melanoma growth, we provide a rationale for the therapeutic advantage of the drug combination. 24980831 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Thus, restoration of CYLD and inhibition of JNK and β1-integrin function represent potential therapeutic strategies for treatment of malignant melanoma. 22832488 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Furthermore, Pin1 inhibition also resulted in decreased phosphorylation of Akt and repressed expression of C-Jun N-terminal kinase and pro-matrix metalloproteinase 2, which were associated closely with the development of melanoma. 23067222 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. 18989785 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease LHGDN Together, our findings demonstrate that JNK, and in particular the JNK1 isoform, support the growth of melanoma cells, by controlling either cell cycle progression or apoptosis depending on the cellular context. 18541008 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Together, our findings demonstrate that MAPK-ERK and MAPK-JNK are regulators of CIITA transcription in melanoma, and pinpoint an AP-1-responsive site in the CIITA gene pIII. 17304627 2007